Background:

CDKN2A generates several transcript variants which differ in their first exons. At least three alternatively-spliced variants encoding distinct proteins have been reported, and two are related, named p16-INK4 and p14 respetively, sharing 50% identity. The third one is completely stuctually un-related, called p14(ARF) or p19(ARF). FNab06064 reacted with p16 specifically. P16 plays an important role in regulating the cell cycle, and mutations in p16 increase the risk of developing a variety of cancers, notably melanoma.

Clonality:

polyclonal

Classification:

Primary antibody

Alternative names:

ARF,CDKN2A, CDK4 inhibitor p16 INK4, CDK4 inhibitor p16INK4, CDK4I, CDKN2, CDKN2A, CMM2, INK4, INK4a, MLM, MTS 1, MTS1, Multiple tumor suppressor 1, p14, p14ARF, P16, p16 INK4, p16 INK4a, p16INK4, p16INK4a, P19, TP16

Specificity:

Human, Mouse, Rat

Host:

Rabbit

Isotype:

IgG

Immunogen:

cyclin-dependent kinase inhibitor 2A(melanoma, p16, inhibits CDK4)

Purification:

Immunogen affinity purified

Purity:

≥95% as determined by SDS-PAGE

Calculated molecular weight:

Request info at info@sobekbio.com

Form:

liquid

Applications:

ELISA, WB, IF, IP, IHC, FC

Recommended dilution:

WB: 1:500-1:5000; IP: 1:500-1:5000; IHC: 1:50-1:500; IF: 1:20-1:200

Storage:

PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com